DiaSorin Announces Completion of the Acquisition of Luminex Corporation
Saluggia, July 14, 2021 - DiaSorin S.p.A. (“DiaSorin”; FTSE MIB: DIA) announces it has completed the acquisition of Luminex Corporation (“Luminex”; NASDAQ: LMNX) for a price of USD 37.00 per share that corresponds to a total equity value of approximately USD 1.8 billion.
Through the acquisition, DiaSorin will gain access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the United States. Additionally, this deal will provide access to Luminex’s applications throughout the Life Science industry, supporting access to academic and scientific research, expanding engagement with biopharma companies, and increasing access to clinical multiplexing assays for future Value Based Care projects.
Data Provided by Refinitiv. Minimum 15 minutes delayed.